Citadel Advisors
NEUP

Citadel Advisors’s Neuphoria Therapeutics NEUP Stock Holding History

Citadel Advisors’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$78.7K Buy
+19,331
New +$81.7K ﹤0.01% 12187
2025
Q3 		– Sell
-14,606
Closed -$104K – 14502
2025
Q2 		$104K Buy
+14,606
New +$84.8K ﹤0.01% 11315

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Citadel Advisors's NEUP Position: Q1 2026 in Review

Citadel Advisors opened a new position in Neuphoria Therapeutics (NEUP) in Q1 2026: 19,331 shares worth $78.7K. The stake represents ﹤0.01% of the portfolio and ranks #12187 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in NEUP as recently as Q2 2025.

Citadel Advisors first reported a position in NEUP in Q2 2025 and has held it in 2 quarters since. The position peaked at $104K in Q2 2025. 19 funds tracked by Wall St. Rank hold NEUP as of Q1 2026.

  • Citadel Advisors held 19,331 shares of Neuphoria Therapeutics worth $78.7K as of Q1 2026.
  • Neuphoria Therapeutics was a new Citadel Advisors position in Q1 2026.
  • Neuphoria Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12187 holding.
  • Citadel Advisors first reported a position in Neuphoria Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • Citadel Advisors's Neuphoria Therapeutics position peaked at $104K in Q2 2025.
  • 19 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.